

Addition and Correction to “High-Performance Concurrent Chemo-Immuno-Radiotherapy for the Treatment of Hematologic Cancer through Selective High-Affinity Ligand Antibody Mimic-Functionalized Doxorubicin-Encapsulated Nanoparticles”

Kin Man Au, Rod Balhorn, Monique C Balhorn, Steven I Park,* and Andrew Z Wang*

ACS Cent. Sci. 2019, 5, (1), 122–144. doi [10.1021/acscentsci.8b00746](https://doi.org/10.1021/acscentsci.8b00746)



Cite This: *ACS Cent. Sci.* 2024, 10, 1115–1116



Read Online

ACCESS |

 Metrics & More

 Article Recommendations

On Figure 7b, the lung H&E images preserved from mice treated with Free SHAL and free Dox were not not display correctly. We just recently became aware of this issue. The problem is likely caused by improper preparation of histological specimens that led to the same histological specimens being split into 2 different experimental groups. In this case, the image for the “Free SHAL” group is incorrect (as noticed by the reader). Since we inspected 3 specimens per experimental group, we are writing to request the correction of this figure with a correctly displayed H&E image.

The conclusion remains unchanged since no two control treatment groups would induce double-strand DNA breaks.

For each treatment and control group, we recorded histological images of more than one tumor. This erratum does not affect any of the experimental results, discussions, or conclusions reported in the paper. The authors sincerely apologize for this unintended oversight. Steps have been taken to prevent similar problems from occurring in the future.

Published: May 8, 2024



